FDA issues draft guidance on developing weight loss drugs
New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.
Devex9mon
Raffat Malik
Interested in learning more about this Devex member? With a Recruitment Account, you can view the full profile & CV for this member and other professionals around the world. Click here to know more!
Hosted on MSN24d
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
In testing, duvakitug proved to be well tolerated with no new safety issues. Evercore ISI analyst Umer Raffat noted the placebo-adjusted responses to Teva's drug were better than the same for ...
Business Insider1mon
Pfizer (PFE) Gets a Buy from Evercore ISI
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $25.57. Pick the best stocks and ...
Business Insider1mon
Evercore ISI Remains a Buy on Amgen (AMGN)
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s shares closed yesterday at $301.44. According to TipRanks ...